Anti-Bcl-XL Antibody [SZ3-03]

HUABIO

Anti-Bcl-XL Antibody [SZ3-03]

7

Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

WB,IF-Cell,IF-Tissue,IHC-P,FC,IP

Research Use Only

Monoclonal

SZ3-03

1 mg/ml

Unconjugated

BCL2L1

BCL2 like 1

BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52, bcl-2-like protein 1, apoptosis regulator Bcl-X, protein phosphatase 1, regulatory subunit 52

Rabbit

IgG

Bcl-2-like protein 1

It is a well-established concept in the field of apoptosis that relative amounts of pro- and anti-survival Bcl-2 family of proteins determine whether the cell will undergo cell death; if more Bcl-xL is present, then pores are non-permeable to pro-apoptotic molecules and the cell survives. However, if Bax and Bak become activated, and Bcl-xL is sequestered away by gatekeeper BH3-only factors (e.g. Bim) causing a pore to form, cytochrome c is released leading to initiation of caspase cascade and apoptotic events. While the exact signaling pathway of Bcl-xL is still not known, it is believed that Bcl-xL differs highly from Bcl-2 in their mechanism of inducing apoptosis. Bcl-xL is about ten times more functional than Bcl-2 when induced by the chemotherapy drug, Doxorubicin and can specifically bind to cytochrome C residues, preventing apoptosis. It can also prevent the formation of Apaf-1 and Caspase 9 complex by acting directly upon Apaf-1 rather than Caspase 9, as shown in nematode homologs.

Human

Human

Mouse,Rat

-20°C,2°C to 8°C

41116161